Literature DB >> 12107689

Seven cases of fungemia with Saccharomyces boulardii in critically ill patients.

Thierry Lherm1, Claire Monet, Bruno Nougière, Muriel Soulier, Daho Larbi, Christian Le Gall, Daniel Caen, Claire Malbrunot.   

Abstract

Saccharomyces boulardii (Sb) is a particular strain of Saccharomyces cerevisiae (Sc). This viable yeast is used in intensive care adult patients, delivered in packets of 500 mg, for preventing diarrhea associated with antibiotics or enteral feeding at a regimen of 1-2 g/day. Between June 1996 and October 1998, seven cases of fungemia with Sb occurred in a 12-bed intensive care unit (ICU). All the patients concerned were severely ill patients, mechanically ventilated, treated by broad spectrum antibiotics with central venous catheter and were pretreated with Sb, except for one patient. In this study, Sb was identified by specific mycologic methods and confirmed the genomic identity between isolates of blood culture and yeasts from the treatment packets, contrary to a few other reports concerning Saccharomyces species published in international literature. The hypothesis discussed for explaining these cases of Sb fungemia are: (1) an intestinal translocation of Sb administered at a high dosage in severely ill patients, (2) a contamination of the central venous catheter, especially in the patient not pretreated with Sb and (3) a massive colonization of critically ill patients by the yeast as has been reported for Candida species. We note that cases of fungemia with Sc and Sb have become more and more frequent in the international literature during the last 10 years and we do not recommend administering Sb treatment in critically ill patients.

Entities:  

Mesh:

Year:  2002        PMID: 12107689     DOI: 10.1007/s00134-002-1267-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  41 in total

Review 1.  Hospital-related outbreaks due to rare fungal pathogens: a review of the literature from 1990 to June 2011.

Authors:  E C Repetto; C G Giacomazzi; F Castelli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-03       Impact factor: 3.267

Review 2.  Future therapies for inflammatory bowel disease.

Authors:  Stephen J Bickston; Lawrence W Comerford; Fabio Cominelli
Journal:  Curr Gastroenterol Rep       Date:  2003-12

3.  Use of probiotics in gastrointestinal disorders: what to recommend?

Authors:  Elizabeth C Verna; Susan Lucak
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

Review 4.  Intestinal microbiota and blue baby syndrome: probiotic therapy for term neonates with cyanotic congenital heart disease.

Authors:  Collin L Ellis; John C Rutledge; Mark A Underwood
Journal:  Gut Microbes       Date:  2010 Nov-Dec

Review 5.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 6.  Risk and safety of probiotics.

Authors:  Shira Doron; David R Snydman
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

7.  Determination of MICING: a new assay for assessing minimal inhibitory concentration for invasive growth.

Authors:  J Zupan; Z Tomičić; P Raspor
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-01-27       Impact factor: 3.267

8.  Saccharomyces boulardii fungemia caused by treatment with a probioticum.

Authors:  Julie Bjerre Thygesen; Henning Glerup; Britta Tarp
Journal:  BMJ Case Rep       Date:  2012-03-27

9.  Trends in Clostridium difficile Disease: Epidemiology and Intervention.

Authors:  David J Riddle; Erik R Dubberke
Journal:  Infect Med       Date:  2009

Review 10.  Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.

Authors:  Laura Marinela Ailioaie; Gerhard Litscher
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.